ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

XBIO vs CANF // NET PROFIT MARGIN

Xenetic Biosciences Inc. (NASDAQ) VS. Can-Fite Biopharma Ltd each representing two (2) (NYSE) • 15-METRIC TALLY: XBIO 4 — CANF 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XBIO VS. CANF) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC XBIO CANF SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -30.30% -35.00% +4.70 XBIO /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin ACTIVE -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 19.00% -39.90% +58.90 XBIO /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 XBIO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.5 23.6 +19.97 XBIO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $5.0M $5.0M -$64.8K CANF /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR XBIO REV CANF REV XBIO GROSS % CANF GROSS % XBIO FCF CANF FCF
FY 2025 $3.0M $405.0K — — -$2.3M -$9.0M
FY 2024 $2.5M $674.0K — — -$2.8M -$7.6M
FY 2023 $2.5M $743.0K — — -$4.1M -$8.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XBIO // BETA —
CANF // BETA —